APA

Rouffy J., Dreux C., Goussault Y., Dakkak R. & Renson F. J. (19761020). Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV). : Arzneimittel-Forschung.

Chicago

Rouffy J, Dreux C, Goussault Y, Dakkak R and Renson F J. 19761020. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV). : Arzneimittel-Forschung.

Harvard

Rouffy J., Dreux C., Goussault Y., Dakkak R. and Renson F. J. (19761020). Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV). : Arzneimittel-Forschung.

MLA

Rouffy J, Dreux C, Goussault Y, Dakkak R and Renson F J. Atilipidemic drugs. Part 5: Evaluation of the hypolipidemic effect of LF 178 in 191 patients affected by the atherogenic form of endogenous hyperlipoproteinemia (types IIa, IIb and IV). : Arzneimittel-Forschung. 19761020.